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The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual
meeting focused on impending change, innovation, and future challenges facing early
phase drug development as we move into the second decade of the 21th century. The
meeting opened with discussion around the technical revolution in pharmaceutical
medicine over the 4 decades since the AHPPI was founded and how transformative
technologies have accompanied the introduction of processes such as physiologically
based pharmacokinetic modeling. During the meeting examples were presented of how in
terms of the development of new therapies, the classic phases of clinical drug
development are becoming a thing of the past and the lines between the phases have
begun to blur, particularly in the field of oncology. The contribution that monoclonal
antibodies have made to medicine and the next chapter in their design and use was also
discussed. A representative of the UK’s Medicine and Healthcare Products Regulatory
Agency discussed the increasing numbers of requests to approve complex innovative
design trials, how novel trial designs are impacting on the traditional linear “phase”
approach to drug development and the common pitfalls associated with them.
Guidance was provided from a regulator’s viewpoint on what was meant by the term
“novel design” and how to submit successful trial applications for such complex trials. In an
Oxford-style debate, the audience discussed the motion that “there is no longer a need to
include placebo subjects in early clinical trials.” The keynote speaker focused on delivering
change in complex environments such as the field of drug development. The afternoon
session included presentations on the challenges associated with drug product design,
the complexities within non-oral dosage forms and proposed newmethods of formulations
for drug delivery. Presentations were also given on advances in mechanistic and
computational pharmacokinetic modeling and how they have proved to be valuable
tools to rationalize and facilitate the process of drug development.
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INTRODUCTION
Founded in 1988, the Association for Human Pharmacology in
the Pharmaceutical Industry (AHPPI; www.ahppi.org.uk)
provides a forum for discussion regarding practical and
regulatory aspects of early clinical development of new
medicines and continuing education in clinical pharmacology.
The AHPPI’s annual meeting held in London on October 11,
2019 focused on the impending changes, innovation and future
challenges of early phase drug development and strategies that
might be employed by the pharmaceutical industry to address
them. By bringing together stakeholders from a range of
disciplines including drug development, data intelligence
platforms, research organizations, government science policy
and clinical trials regulation, the AHPPI committee created an
opportunity to share engaging, comprehensive and balanced
viewpoints from a broad range of professionals within the
pharmaceutical industry. This report summarizes the key
observations from the meeting.
MORNING SESSION
The meeting was opened by the AHPPI Chairman, Dr. Tim
Hardman who briefly discussed the technical revolution in
pharmaceutical medicine over the 4 decades since the AHPPI
was founded. He described how we have seen a multitude of
changes ranging from the introduction of complex new study
designs to new parameters such as genomics, transcriptomics,
and proteomics. The development of transformative technologies
has been accompanied by novel investigative processes such as
physiologically based pharmacokinetic modeling (PBPK). These
modifications have come as a series of “bolt-on’s” that challenge
the established clinical framework described within the Good
Clinical Practice and International Council for Harmonisation.
Dr. Hardman spoke about five key areas he believes are most
likely to sit at the heart of future clinical trials: our understanding
of disease; the appearance of novel mechanisms of action; the
efficiency of the drug development process; reimbursement for
newmedicines; and ownership of data and the analytical methods
used to interrogate it.
After welcoming the conference delegates, Dr. Hardman
introduced Professor Emma Baker from St. Georges
University, London who chaired the morning session.
Professor Baker spoke about a growing skills gap within the
pharmaceutical industry and how the newly introduced BSc in
clinical pharmacology launched by St. Georges University,
London was designed to partly address this challenge. The BSc
course places emphasis on providing young graduates with a
working understanding around drug development, which is
expected to facilitate their introduction into the
pharmaceutical industry and reduce the time it takes for them
to make useful contributions. Professor Baker expressed how the
training course was attracting students from less traditional
backgrounds who were applying their knowledge most
effectively in this course.
Phase I Trials in Patients With Cancer a
Vision of 2020 and Beyond: Professor
Duncan Jodrell (Director, Cambridge
Cancer Trials Centre, United Kingdom)
Professor Jodrell described how, as an integral part of the Cancer
Research UK Cambridge Centre (CRUK), the CCTC was
supporting and delivering clinical and translational research.
The goal of the CRUK Cambridge Centre is to improve
patient outcomes through application of its research findings
and to conduct a wide range of clinical trials in people at risk of
cancer or with established early or late stage cancers, primarily at
Cambridge University Hospitals NHS Foundation Trust. With
over 250 patient referrals annually seeking inclusion in early
phase clinical trials from across the East of England, the CCTC
has a comprehensive understanding of the challenges associated
with delivering complex clinical research in different disease
populations, evaluating novel research approaches.
In terms of the development of new therapies, the classic
phases of clinical drug development are becoming a thing of the
past; the lines between the phases have begun to blur. The
advantages and challenges associated with the inclusion of
patients in Phase I trials and the building of a science-driven
portfolio of early phase trials at Cambridge were discussed.
A specific focus has been assessment of combination strategies,
achieved in part by evaluating preclinical growth inhibition data
in various cancer cell lines. Establishing an understanding of the
combination data generated by these studies is not
straightforward. In a majority of cases, interpretation of dose
response data requires appropriate mathematical models and the
software to implement them. Existing models proved limited and
members of the Jodrell group developed the COMBENEFIT
software tool (Cancer Research UK Cambridge Institute, 2019).
In oncology, first in human studies are performed in patients,
in contrast to many other disciplines. Advantages associated with
involving patients in Phase I cancer trials are the early inclusion of
a relevant target population, the option to directly monitor for
improvements in quality of life and the prompt identification of
anti-tumor activity. Challenges associated with the inclusion of
patients in Phase I trials result from the confounding effects of
underlying pathology and previous treatment such as impaired
renal or hepatic function.
There was discussion over how success in identifying novel
therapies often depends on investigating orphan drugs in varying
combinations tested in small, molecularly defined patient
populations responding to the diverse (almost unique) nature
of the disease. Drug combinations are frequently employed in
patients with cancer. He described how mathematical modeling
and an understanding of biological pathways have been useful in
identifying the key nodes to target in signaling networks that are
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involved in cancers. Inclusion of a single biomarker in a basket
trial for multiple tumor types can provide untold insights.
The Jodrell group has undertaken collaborative research with
AstraZeneca to identify combination partners for use with
gemcitabine, an agent frequently used in patients with
pancreatic cancer and other tumor types. Using the
COMBENEFIT software, gemcitabine was indicated as being a
highly synergistic agent with drugs targeting the DNA Damage
Response (DDR), in both cell lines and also demonstrating tumor
shrinkage in genetically engineered mouse models.
Conventional methods to calculate dosage levels of new and
combination drugs have tended to be based on their maximum
tolerated dose (MTD). However, simply combining two agents at
their MTD may not prove to be optimal in terms of their
synergistic interaction or tolerability profile. Professor Jodrell
suggested that it is possible to achieve a more thorough
interrogation of the interaction of two agents, using model-
based approaches to describe an “interaction surface” for the
two agents, as described from in vitro experiments investigated
with the COMBENEFIT software.
It was noted that the debate remains as to whether it is
preferable to test the biology of a tumor before initiating
treatment with “recommended” doses. To address these
challenges, the CCTC is leading a collaboration with
AstraZeneca to standardize methods of tumor testing by
employing a central review board that makes suggestions for
appropriate clinical trials and patient inclusion.
The presentation was concluded by introducing the concept of
promoting dose expansion in patients using a dual agent dose
escalation strategy to establish combination toxicity profiles and
how a solution would be to enroll patients across subsequent
cohorts with gemcitabine as a potential sensitizer, to aid
modification of the doses for both drugs.
Dr. Phil Barrington (TranScrip Partners LLP,
United Kingdom): Monoclonal
Antibodies—Predicting the Next Chapter
The presentation began with an introduction to monoclonal
antibodies providing a brief history of their development. Dr.
Barrington summarized key milestones from their history: the
first “indirect” use of antibody therapy with cowpox immunization
against small pox by Jenner in 1796, through the development of
“anti-venoms” in the 19th century that came into common use in
the 1950s. A key milestone was the identification of a method to
generate large amounts of antibodies (Milstein and Köhler in
1975). He discussed how since the introduction of the first
monoclonal antibody for clinical use and the means to
construct human monoclonal antibodies in the mid-1980s, they
have become an important role in the treatment of a broad range of
conditions, many of which previously had no clinical solution.
Their involvement in medicine has been growing exponentially
and in a period of 3 years from 2016 to 2018, 27 new antibodies
were approved for clinical use by the US Food and Drug
Association (over 20% of all FDA approval that year). He also
noted that they have become commercially important making up
seven out of the top 10 selling products in 2018.
In considering the next stage of development for monoclonal
antibodies, attention was drawn to different structural forms of
antibodies and what we have learned from species differences,
placing emphasis on what has been learned of camelid and shark
biology. Our knowledge of antibody biology has expanded the
field to include heavy chain only and nanobody molecules,
stereospecific and catalytic monoclonals as well as check point
agonist monoclonal antibodies and intrabodies.
The concept of nanobodies as the current “new kid on the
block” in terms of their clinical potential. In contrast to
conventional monoclonals, nanobodies have low molecular
weights and offer the potential to cross the blood brain
barrier. They also have better solubility profiles, tissue
penetration, and stability. Additional benefits include the ready
availability of alternate “starting” parent molecules in yeast
libraries, their ability to undergo conjugation (making them
useful for new approaches to “imaging”) and possible lower
immunogenicity profile.
Caplacizumab was the first nanobody to be approved by the
FDA in 2019 and is used to treat the life-threatening autoimmune
disease, acquired thrombotic thrombocytopenic purpura.
Caplacizumab targets the von Willebrand factor protein that
mediates platelet adhesion and inhibits the interaction between
the von Willebrand factor protein and platelets. A potential
limitation with caplacizumab is one that limits the utility of all
candidate nanobodies, a relatively short half-life as a consequence
of their high renal clearance. This means daily administration of
the nanobody is required in an era when treatments are being
selected to have longer periods between doses.
It was noted that most conventional monoclonal antibodies
exhibit linear epitope recognition and that stereospecific moieties
that recognize three dimensional molecular configurations have
the potential to introduce novel opportunities. For example,
incorporating stereospecific recognition provides bispecific
monoclonals with the potential to detect membranous
antigens on cancer cells, which are not readily accessible with
conventional linear-specific monoclonal antibodies. Attention
was drawn to ecto-S-nucleotidase as a promising immuno-
oncology target. The example of MEDI9447 was used to
demonstrate how it is possible to combine two different
attacking “mechanisms” in one candidate dimer, those of
crosslinking and steric blocking. Another opportunity
discussed was catalytic antibodies, which not only “recognize”
their target antigen but also facilitate its degradation. The
audience generally agreed that catalytic antibodies represent a
potentially powerful new class of antibodies.
There was discussion over the expansions in topical
administration through use of Fabs and nanobodies have been
investigated for the treatment of skin diseases such as psoriasis
and atopic dermatitis.
Dr. Barrington described the mechanism of action behind
bispecific monoclonal antibodies. To create a bispecific antibody,
the Fab can be cut, which effectively splits the antibody into two
halves. As the Fab is comprised of both heavy and light chains, in
order to stop the Fab from falling apart, a “linker” molecule is
used to produce a “single chain variant” and these can be “added”
onto the structure of an antibody. An alternative method is the
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“knob in hole” technique where a pocket is created on one end
with a protrusion on the other, which allows the heavy chain to
align correctly. Potential issues with bispecific antibodies are that
they tend to become “fixed dose” combination products, which
are not generally favored by physicians. There may also be issues
with the parent molecule construction. The obvious approach
would be to have a 1:1 ratio for your specific apparatus, and yet it
is possible to select any ratio—whichever gives the best results.
Theoretical target binding shows that 2:1 or 3:1 ratios are
optional. The frequency of targeting binding is unpredictable
and is dependent on the molecular weight of the antibody format.
There is also a question as to whether bispecific antibodies are
more immunogenic and this will need to be thoroughly assessed
before they can be adopted widely.
Potential methods of oral delivery of peptides and proteins
through the selective use of lipids, formulation for lacteal
absorption, paracellular transport, with “tight junction”
openers, promotion of diffusion via the mucus layer in
conjunction with nano-objects that may facilitate diffusion via
transcellular pathways, permeation enhancers and gastric
injection of proteins were described. However, issues generally
associated with these methods include; their requirement to be
administered after fasting; possible damage to the gastrointestinal
tract; and reliability of their delivery in a setting where
bioavailability is unpredictable challenges regulatory approval
requirement. Alternative expression systems may enhance such
approaches through the co-opting of genetic modification
techniques. New methods of genome editing are expected to
become available in the near future for transgenic animal
expression systems where proteins can, for example, be
expressed in milk.
In revisiting the high molecular weight limitation associated
with monoclonal antibody that restricts their tissue and cellular
penetration, the concept of intrabodies where “antibodies meet
gene therapy was introduced.” Intrabodies are antibodies that are
expressed intracellularly and remain within the cell cytosol or
endoplasmic reticulum. To produce intrabodies, DNA is
introduced into the cell by retroviral delivery systems often
used in gene therapy. This technique allows highly specific
targeting of intracellular proteins. It is postulated that this
approach could reduce the potential of unwanted adverse
effects associated with systemic exposure to antibody therapies,
although no such therapeutic approach has yet been tested in
humans. Nevertheless, in vitro and in vivo studies in a variety of
animal models have shown promising activity.
The potential for checkpoint antagonist and agonists was also
discussed briefly in closing the presentation, giving examples of
molecules in development as well as the opportunities when
targets are combined in bispecific molecules.
Challenges of Novel Trial Designs on Clinical
Application Approval: Dr. Kirsty Wydenbach
(Medicine and Healthcare Products
Regulatory Agency, United Kingdom)
The Medicine and Healthcare Products Regulatory Agency
(MHRA) are seeing more and more drug development
pathways employing clinical trials that address multiple
clinical questions in a single application and which may be
termed “complex innovative design trials.” Dr. Wydenbach
spoke about how novel trial designs are impacting on the
traditional linear “phase” approach to drug development and
the common pitfalls associated with them during the initial stages
of regulatory approval. Guidance was provided from a regulator’s
viewpoint on what wasmeant by the term “novel design” and how
to submit successful trial applications for such complex clinical
trials.
It was acknowledged that the MHRA may previously have
been considered overly cautious in its approach to clinical trial
applications that have attempted to employ less traditional study
designs. However, they have come to recognize the benefits that
can be achieved by adopting a flexible approach to the way clinical
trials are conducted. They have been actively tracking all novel
designs being requested. In the future, although the application,
review and approval methods will be the same regardless of the
trial design, they expect to take a more proactive approach to
innovative ways to develop new medicines. The agency plans to
share more of the metrics they collect on the trials they approve
and provide more guidance to sponsors on how to get their trial
approved, acknowledging the level of guidance that has already
been achieved by the US Food and Drug Administration.
Feedback from organizations working with the MHRA
suggests that sharing its information on the design and
implementation of trials will be beneficial to the industry as a
whole. In response to this feedback, a group of stakeholders from
organizations within the pharmaceutical industry have been
developing a consensus paper that will cover all aspects of trial
design and will bring to light key training and education
requirements.
A “recommendation paper” on the initiation and conduct of
complex clinical trials developed by the Clinical Trial
Facilitation Group, a European regulatory forum spanning all
member states of the EU, was published in February 2019
(European Clinical Research Infrastructure Network, 2019).
It is hoped that the guidance provided will increase
harmonization and reduce the number of trial applications
that are rejected by agencies including the MHRA. Master
protocols are frequently associated with basket, umbrella and
platform trial designs where the core protocol plus sub-
protocols can be submitted for approval either as individual
clinical trials or as part of a single complex clinical trial. It is
generally agreed that master protocols must describe the overall
clinical trial design including components and operational
aspects applicable to any related sub-protocols (such as the
rationale behind the trial objectives, endpoints, and risk-benefit
assessments), shared procedures relating to safety monitoring
and reporting as well as subject screening, eligibility, and/or
treatment allocation.
The traditional phases of clinical trials were described as
becoming somewhat out-dated and the emergence of seamless
development in the form of trials that encapsulate aspects of
several phases of development within single studies. When
incorporated appropriately into clinical programs, whether
they are basket, umbrella, matrix, or platform trials, they offer
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the potential for accelerated development reducing the time
normally taken for researchers to get access to data generated
by individual studies. However, a number of pitfalls are
commonly associated with clinical trial applications for these
novel types of trials that have tended to impact on whether or
not they gain regulatory approval. Sponsors working with
complex trials often overlook the possibility that changes to
study conduct during the course of implementing adaptive
modifications can have an impact on the primary objective of
a trial, so that it no longer aligns with the original hypothesis.
Frequently there is no clearly stated “end” to a study. Sponsors
also often make modifications to their protocols without
properly qualifying the reasons for such changes in the form
of a formal rational. This tends to serve as a red flag to regulatory
agencies, raising questions. Often, the lack of clear explanations
behind changes results in the delay of an application, or even
rejection in those cases where sponsors fail to provide adequate
justifications.
The MHRA has adopted a pragmatic approach when
considering clinical trials applications employing novel
designs. In providing her “top tips” to ensure the success
initial drug trial applications, she advised that Sponsors
clearly justify their choice of trial design, the investigations
and their use of investigational medicinal products, where
relevant providing their reasoning behind decisions to
employ adaptive designs over a more traditional approach
(Medicines and Health Regulatory Agency, 2019). Criteria for
closing or expanding a study group should be included in the
initial application if the Sponsor feels there is the slightest
possibility of this happening. It was noted that the MHRA
require scientific reasoning for the introduction of changes
and will rarely find logistical benefits alone acceptable—an
“easier” design is not sufficient explanation to justify a
change to your initial trial application. A list of potential
adaptations that the Sponsor may implement must be
included at the outset. For example, if a Sponsor considers
that they may include an additional study cohort, then they are
more likely to achieve a positive response and face less resistance
from the agency if they introduce this possibility as early as
possible.
Dr. Wydenbach discussed how, when submitting a substantial
amendment to complex protocols, a narrative description of
changes does not necessarily provide an easy way for assessors
to make a comparison between original and amended
documents and advised that it can be better to use tables as a
way of presenting modifications. She indicated that Sponsors
should put more effort into describing the thought processes
behind any modifications. It was highlighted that for
amendment submissions there are no options for the agency
to respond by questioning the Sponsor’s approach and if the
agency is left in any doubt over the acceptability of a
modification, it has no option other than to reject the
submission. It was also advised that Sponsors ensure that
their control groups remain valid throughout the trial as the
requirements or purpose of such a group often shifts when
changes are made to the treatment pathway. If changes are made
to what happens in the control group, particularly where a
control group is common to several arms in a trial, then benefits,
risks and safety aspects relating to this group also need to be
reassessed. A clear explanation should also be provided as to
why any new, additional arms were felt to be appropriate as part
of an amendment rather than completing the current study and
introducing a new trial.
The presentation was concluded by describing how in the
future the MHRA will actively promote the use of complex and
innovative trials, taking a more proactive stance and offering
greater assistance with the implementation of novel protocol
designs. The MHRA are working toward maintaining the UK
as a competitive space for the conduct of clinical trials in
partnership with Sponsors and CROs. To achieve this, it is
currently developing a novel trials implementation plan which
will focus on engagement with stakeholders, feedback from
workshops, internal training, providing guidance, and
collaborative engagement with organizations such as the
National Institute for Health Research and the National
Institute for Healthcare and Care Excellence. The importance
of communication between the Sponsors and the MHRA in
delivering successful trial applications and stated “ask for
advice” was stressed. However, she added that Sponsors
should not be surprised by significant questions at the time of
an application if they do not follow the guidance provided
to them.
Value of Placebo in Phase I Studies; an
Oxford Style Debate: Dr. Peter Dewland
(MAC, United Kingdom) and Dr. Sven van
Dijjkman
A great majority of early phase clinical studies follow a blinded,
placebo-controlled design, often involving a small number (six to
eight) of subjects receiving doses of active treatment and one or
two subjects being given placebo. Studies usually investigate
multiple dose levels, each mirroring the same placebo-
controlled design. It is the generally held belief that pooling
placebo data from each dosing cohort (typically somewhere
near a number equal to the number of active treatment
subjects included in a single dose level) provides a cohort that
can be used to assess the actions of the “active” therapy. As such,
randomized, double-blind placebo-controlled trials have come to
be considered the “gold standard” approach to clinical study
design for producing data untainted by bias. However, beyond
anecdotal opinion, there are very few published evaluations that
provide empirical data to support the ready acceptance that such
study designs are necessary to provide high quality data, while
evidence suggests that the method itself may be flawed. In an
Oxford Style debate, Dr. Sven van Dijkman defended the motion
that “there is no longer a need to include placebo subjects in early
clinical trials.” Dr. Peter Dewland (MAC, United Kingdom)
countered the motion and the session was chaired by Dr.
Emma Baker (St. Georges University, London, United
Kingdom). A poll of the audiences’ opinion on the motion
was performed prior to the proceedings. Only one member of
the audience felt that the proposed concept was acceptable and
placebo subjects were unnecessary.
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Dr. Sven van Dijkman opened his presentation by questioning
whether the motion represented a human or medical perspective.
He reasoned that although factors such as pharmacokinetics,
pharmacodynamics, tolerability, and safety need to be quantified
and appropriate dosages determined during early development,
the use of placebo administered subjects in Phase I studies does
not provide useful insight into an agent’s toxicity, safety, or
tolerability. There is some skepticism as to whether data of
any real value can be obtained by comparing the behavior of
new molecules in healthy subjects with those given placebo. He
reasoned that it could easily be argued that if any comparison is
necessary then placebo data generated during a trial could be
replaced with historical data from previous studies. Comparator
data could also be used from pre-dose samples, time-matched
baseline assessments that are often conducted for such studies or
past data from placebo subjects included in similar studies. This
would mean that healthy subjects avoid the exposure of any risks
associated with placebo and procedures during participation in a
clinical study, while also reducing the cost, complexity, and time
taken to run early phase trials.
Despite the lack of scientific support, Dr. Dijkman stated that
placebo drugs are usually administered in Phase I trials to prove
that “snake oil” is not being sold, and yet, he noted the small
number of placebo subjects typically included would not be
sufficient to determine the unknown effects with any level of
confidence. Most serious adverse events are rare and their signal
cannot be detected in small groups thus a placebo group would be
unlikely to provide beneficial data or insights into the Phase I
setting. Furthermore, the use of placebo is associated with “highly
variable outcomes,” making it difficult to establish early signs of
risk and efficacy by comparing the active drug against the
placebo. Psychosocial and cultural factors may indirectly
modulate observations with the “inert pill” which, in the end,
fail to produce randomized effects.
A case of a study was related that was conducted with levodopa
in patients suffering from Parkinson’s disease. The study
observed an increase in placebo effects as the likelihood of
subjects receiving the active drug increased. Issues were raised
of two specific cases where study designs included placebo
groups, but failed to predict any risks, namely TeGenero, the
German biotechnology company whose experimental drug,
TGN1412, caused the hospitalization of six men and the Bial
trial, for experimental drug BIA10-2474 resulted in the death of a
study subject. He concluded that in both cases a clearer
understanding of the pharmacology was what was missing and
that the availability of placebo data could not have prevented such
serious outcomes.
A structured modeling approach was proposed to determine
the detection of placebo effect against a dose-response curve.
Observations in difference in subject response might be
observed if historical data was combined with disease
models. There are studies that provide data that predict the
placebo response differentiated from the actual treatment effect
and show the subjects’ profiles change over time with some
diseases. For example, bipolar disorder studies have shown a
clear “placebo effect” over time in large numbers of patients,
from combined data across 11 clinical trials and five different
drugs. Similarly in depression, random fluctuations in bio-
behavioral health were observed in data on 700 patients from
six clinical trials.
The final point was that information given to the subjects in
the trial can determine the size and variability of any placebo
effect. Phase I trials should be given careful consideration to the
inclusion of placebo subjects as they fail to contribute to
predicting serious adverse events or identify clinically relevant
actions of the active compound. The next critical step suggested
in first time in human trials is a shift in paradigm to improving
efficiency of trials through structural modeling instead of
recruiting volunteers. This has the potential to reduce costs
and the burden on trial subjects. Overall, an underlying
exposure-response relationship needs to be established.
Dr. Dewland’s motion described the fundamental rationale
behind Phase I trials. He agreed that the general adoption of
placebo-controlled trials had been based on theoretical reasoning
and intuitive attractiveness rather than a compelling body of data.
He noted that attempts to investigate the benefits of placebo in
clinical trials systematically have been relatively scarce. However,
he referred to the Integrated Research Application System (IRAS)
form, stating the current standards of Phase I trials which are
considered to be a less subjective approach and are conducted to
determine the safety, dose levels of response and first time in
human effect of an investigational medicinal product. A
standardized model approach to placebo data was argued as
not feasible in Phase I trials as all treatments are varied and
differ in mode of action, e.g., biologicals, siRNA, and small
molecules. Equally, it was argued that all humans are different
physiologically thus no two clinical trial populations could
possibly be identical.
It was noted that in the studies presented by Dr. Dijkman in
support of a modeling approach data sharing were mostly
conducted in studies into depression that were larger than
typical Phase I studies and in most of these cases the placebo
groups were required to differentiate between the effects of the
investigational agents. In contrast, Phase I trials are focused on
establishing safety, so the aim to test for effectiveness in a study
may not be justified. The mathematical modeling approach
proposed by Dr. Dijkman’s was challenged as being based
around the “symptomology of the disease” rather than
focusing on understanding the investigational medicinal
product. Subsequently, the use of historical data and disease
models was considered unsuitable for Phase I as the model is
specific. Dr. Dewland concluded with the quote, “if it ain’t broke,
why fix it?” Placebo cohorts are, he argued to provide better
reflective conditions of the trial and active drug.
The audience quizzed both candidates on different aspects of
their presentations. Much of the focus was around establishing
causality of safety episodes in the absence of placebo group with
focus on aspects such as more severe episodes of liver toxicity.
Other discussions focused around unbiased interpretation ofmild
effects without placebo data or observations for comparison and
whether interpretation of data from placebo-free studies would be
susceptible to subjective factors. A suggestion made was that
inclusion of placebo group may contribute to higher statistical
power through accumulation of more data.
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Following the lively discussion, the audience were asked once
again to vote on the two positions. Following the presentations,
14 members (approximately 20%) of the audience had changed
their position from “against” to “for” the motion.
AFTERNOON SESSION
Keynote Address: Dr. Stephen Carver
(Senior Lecturer in Project and Program
Management, Cranfield School of
Management, United Kingdom)
In line with the theme of the conference, Dr. Carver gave an
insightful presentation on delivering successful change. He first
noted that many long-established companies, even entire
industries, are being disrupted by the challenge of change. He
observed that the pharmaceutical industry is a business with its
foundation and profitability firmly rooted in being able to deliver
change, relying on a capacity to disrupt, innovate and regenerate
while constantly being challenged by innate forces that resist
change. These forces not only reside in the government agencies
that manage and regulate the industry but are inherent to the
culture that pervades it. Topically, he referred to Darwin pointing
out that he was not responsible for the commonly guided phrase
“survival of the fittest.” What Darwin actually said was “it is not
the strongest of the species that survives nor the most intelligent.
It is those that are the most responsive and adaptable to change.”
The concept of VUCA was introduced that describes
situational volatility, uncertainty, complexity and ambiguity
and originated from the US Army War College in the 1980s,
on the end of the ColdWar. Change is a common thread that runs
through all businesses irrespective of their size, industry, or age.
Our world is changing rapidly and the science that drives the
pharmaceutical industry is dictating that organizations must also
change quickly. He concluded that those industry players who
address change will thrive while those that do not will struggle.
Many organizations are only equipped with outdated models of
change management, too often reflecting a traditional style of
management ill-suited to a VUCA world.
The presentation summarized the various different types and
drivers of change and the approaches we often see being adopted
in attempts to address them in the context of making a journey by
plane. He described how, when planning a journey, we overlook
many of the risks associated with air travel and how it reflects our
expectations with regards to project management. He also
pointed out how over 50% of change projects fail and asked
the audience whether they would consider flying if 50% of flights
failed. It was highlighted how it is possible to define change in
project management terms as the discipline of paying meticulous
attention to every aspect of a project or program and how this was
just simple common sense. However, as Voltaire remarked, “the
only problem with common sense is that it’s not very common.”
In reviewing the characteristics of organizations well-adopted to
change, Dr. Carver listed: a work-base consisting of people who
thrive on change; have open channels of communication and
feedback; and a flexible work force.
It was pointed out that freeing people up to generate and
develop great ideas is not the same as letting amateurism run
amok. Indeed, one of the key reasons many projects fail comes
down to insufficient focus on the development and training of
great project and change managers, with opportunities for
advancement often being given to the ill-equipped. Rigorous
training and accumulation of experience greatly improves the
ability of leaders to cope with the stresses and strains of designing
and steering change.
These points were illustrated with the dramatic example of
calm decision-making by Captain Chesley Burnet Sullenberger III
when landing his stricken US Airways Airbus in the Hudson
River in 2009. Captain Sullenberger employed his rigorous
training in a crisis, managing huge complexity,
communicating clearly, and knowing what rules to bend in
order to achieve a successful outcome for all stakeholders.
Replaying the voice recording taken during the incident, Dr.
Carver highlighted how quickly things went wrong but also how
all participants remained calm and trusted their training. As with
all disaster scenarios, there were checklists and protocols for those
involved to follow, but in this case, Captain Sullenberger jumped
protocols and used his own judgment. He was equipped to handle
such situation because of previous training he had undergone in
flight simulators.
Dr. Carver introduced the term “complex and complicated”
while describing the daily pattern of air traffic control over
Europe. He discussed how “complicated” refers to systems that
are linear and predictable simply requiring diligence and effort to
master. He noted that systems like air traffic control can simply be
described as complicated. In contrast, complex systems are non-
linear and unpredictable requiring experience to understand and
agility to negotiate (Maylor et al., 2008). There are three
dimensions of complexity: structural, emergent, and socio-
political.
Tackling these dimensions can be difficult and requires
different skill sets. Structural complexity would depend on the
number of factors that need to be considered—patients, people
sites, etc. This is something the pharma industry is good at.
Emerging complexity (the degree to which the world around you
is changing what might be termed- “the unknowable”) requires
the investment of time to understand what is changing, for
example the emergence of new technologies. Socio-political
complexity requires an understanding of how to address a
wide variety of stakeholder issues and relationships; these
might be termed “political” skills. Traditionally, the mastery of
political skills has not been people development priorities in
organizations involved in the pharmaceutical industry. However,
it is apparent that we need to rethink how we prepare leaders and
project managers for the challenge they are facing. The flying
analogy was used to discuss the concept of managing simulations
in the manner of fighter pilots where the situation is constantly
changing. Good managers tend possess two of the three
complexities and so you should alter the make-up of your
team to ensure you cover all potential complexities.
He concluded his presentation by highlighting how research
has indicated that the one complexity most people find difficult to
manage is the socio-political aspect. And yet, it was generally
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agreed within the audience that the area that most clinical
scientists focus on is structural complexity. Dr. Carver closed
stating that if there was a single reason why most trials fail, this
would be it.
The Biopharmaceutical Impact of the
Delivery of Molecular Drugs via Non-Oral
Routes of Administration: Dr. Eddie French
Formulation Consultant, TEKH
Consulting Ltd.
Dr. French introduced the challenges associated with drug
product design, the complexities within non-oral dosage forms
and proposed new methods of formulations for drug delivery. He
noted how fundamental questions are usually raised during the
manufacturing of a drug around issues of dosage, route of
administration, pharmacokinetic profile and mechanism of
action as well as the intended target population. It is generally
considered the responsibility of pharmaceutical scientists to
convert the active ingredient of a pharmaceutical product into
an easily administered dosage form that can be used to deliver the
correct amount of a drug to its proposed site of action. Often the
product itself is presented as raw compound (in a vial), with the
assumption that the issue of formulation is no more challenging
than simple encapsulation or incorporation in a tablet form.
However, getting the formulation right is a complicated,
involving a plethora of technical hurdles and requires
thorough understanding of both the molecular characteristics
of the active ingredient and the biology of the target.
The pharmaceutical suitability of drug candidates is triaged
early during drug development and tends to be based on
computer modeling, high-throughput screening and cell-based
assays that predict pharmacologic activity. It is, however, much
more difficult to predict factors such as drug absorption,
distribution, metabolism, and excretion (ADME), which
typically require evaluation and understanding in both the
in vitro and in vivo settings. The final product may be
adopted into any of a selection of delivery mechanisms: IV,
intramuscular (IM), intranasal (IN), or intradermal (ID)/
transdermal administration. However, oral administration is
still the first line and preferred route of drug delivery. Other
routes, such as ocular or inhaled delivery, have also been
developed for localized, site-specific drug administration. Each
route of administration faces specific barriers against delivery.
Historically (and currently), the standard and most well-
defined route of administration is via oral delivery, where our
understanding has been augmented by mathematical modeling
which has been shown to successfully predict the absorption,
distribution, metabolism, and excretion of oral drugs. Oral drugs
can be easier to assess using precedented in vitromodels that can
employ bio relevant media and well-mapped animal models.
Although some drugs have local effects in the gut, most enter
the systemic circulation to act in other parts of the body. As a
route for delivery the GI tract can be divided into upper and lower
parts. The structure of the GI tract is similar in all segments. The
characteristics and physiology in the small intestine provide good
opportunities for drug absorption which is relatively well
understood as such, the predictive modeling of orally delivered
formulations is reasonably mature with established simulations
and animal models.
Although oral delivery remains the most prevalent, other
routes of administration are widely used, many drugs require
local delivery, e.g., for drugs that cannot be administered orally.
For example, ophthalmic drugs tend to be applied directly to the
eye by drops to increase targeting efficiency and minimize
systemic expose. Similarly, inhalation is the preferred mode of
delivery for local treatment of the lung, which also avoids
potential systemic side effects. It can be used for drugs
needing rapid onset enabled by quick absorption and in
addition this mode of administration has potential for drugs
affected by first-pass metabolism and for macromolecular drugs
that would otherwise need to be injected. Transdermal delivery is
sometimes considered for drugs that undergo significant or
variable first-pass hepatic metabolism or drugs that would
benefit from steady plasma concentrations enabled by a
controlled release in the form of a patch, but is very
dependent on and limited by the physiochemical properties of
the drug. The global market for non-oral drugs is expected to
double from its current value of about $45 billion within the
5 years.
Dr. French noted that generally for injectable drug candidates
early clinical work is conducted using IV administration for the
sake of speed and convenience, but many drugs may later move to
alternative injectable routes of administration that are envisaged
to be the way final product is given to patients, e.g., subcutaneous
or intramuscular injection (IM). This approach has been
relatively successful; however, bridging between the dosage
forms can be complex as in vitro experiments don’t give a true
picture of delivery to a human and many animal models can
similarly be non-representative. For example, the dosing levels
between an IV and subcutaneous (SC) route are not
interchangeable and require different formulations and/or
volumes. Equally, there is a misconception that administration
by SC or IM gives 100% bioavailability but this is not the case.
When assessing a SC delivery system using animal studies to
predict bioavailability there is a high level of species and molecule
dependency that needs to be taken into account. The ADME will
also depend on the characteristics of the drug for example, with
higher molecular weight molecules (greater than about 16 kDa)
being distributed from the injection site via the lymphatic system
whereas smaller molecules will distribute by lymph and directly
to the capillaries. Dr. French went on to describe the impact the
skin’s adipose tissue (body mass index and gender dependent)
and connective tissue (age) along with depth of needle
penetration depth impacts on dose.
How biopharmaceuticals behave immediately after SC
administration is still not fully understood. Factors that
influence the percentage bioavailability for SC delivery such as
concentration, pH, lipophilicity, protein binding and metabolism
directly influence the release from the injection site. Tools are
becoming available to help map this behavior. The “Scissor”
technology was developed by Pion Instruments in conjunction
with the University of Bath. Scissor is an instrument that can
simulate the stress conditions and environmental transitions that
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a biopharmaceutical drug experiences when injected
subcutaneously. The technique has been used for large
macromolecule and peptide sand could be could be extended
to the application of small molecules. It was expressed that the use
of such instruments provide a good foundation for understanding
the factors that influence delivery via the subcutaneous route and
enable more rationale formulation design. Overall, he concluded
that the SC route of administration offers a great deal of potential
as a route of delivery for manymolecules but requires a significant
“understanding” of the many variables involved to facilitate
rationale formulation design and any bridging between
injectable systems.
For the last part of his talk, Dr. French focused on factors he
understands to be the key elements which impact on the success
of dry powder inhaler drug delivery to the lungs (Tristan et al.,
2009). Dry powder inhalers (DPIs) are an important delivery
system for many drugs used in respiratory diseases. They serve a
good delivery option for various patient populations, and may
help to overcome several limitations associated with other types
of inhalation delivery systems (e.g., accuracy and reproducibility
of the delivered dose, patient compliance and adherence issues, as
well as having a better environmental profile). There are more
than 20 different dry powder inhalers on the market delivering
active pharmaceutical ingredients for local and systemic
therapies. Dry powder inhalers demonstrate varying
performance levels depending on the mechanism of
deagglomeration, aerosolization, dose metering accuracy, and
the inter-patient variability. During development,
manufacturers focus on improving aspects characteristic of
their specific DPI devices, depending on the intended type of
application and specific associated requirements.
Inhalation devices are designed to deliver a predefined dose of
a drug reproducibly to the central and small airways or alveolar
region of the lung. Particles with a mass median aerodynamic
diameter of 1–5 μm are effectively deposited; scientists have
become adept at modeling and predicting deposition of
particles in the lung. However, a broad range of factors affect
delivery to the site of absorption and the eventual drug
absorption. Using this knowledge and depending on
therapeutic need, different drug modalities can be targeted to
different areas of the lung. For many respiratory diseases the
target area is the central airways. Local treatment is desired as it
involves delivery to the target tissue, negating the necessity for
high systemic exposure which can be associated with unwanted
side effects. The approach is different when the lung is employed
as a portal for systemic delivery under such circumstances the
target for drug delivery is the deep lung facilitating allows alveolar
absorption. Permeability in the alveolar tissue tends to be high,
the available surface area is large and enzymatic degradation is
low. Consequently, the process of absorption is less limited
(molecule dependant) and delivery becomes largely dependent
on transport to the alveolar surface, which depends mostly on the
delivery system.
Animal models can be useful for evaluating the fate of inhaled
materials and providing valuable information that can be
explained later in inhalation product development. When
selecting the appropriate animal model, many parameters are
considered, including lung structure, disease pathology, and for
macromolecules the immunological similarity to humans.
Although the data obtained from preclinical studies is valuable
in advancing inhalation drug delivery, extrapolation to humans is
not straightforward due to the differences in the physiological
differences across species and the mode of inhalation. For
example, rats are obligate nasal breathers primary local impact
surfaces for drug being inhaled will differ from larges species and
humans.
The use of traditional in vitro dissolution techniques for DPI
formulations do usually to correlate well with in vivo
pharmacokinetic data requiring more advanced and well
thought through models to help us predict exposure levels in
humans. As a comparison dissolution in simulated gastric and
intestinal fluids in combination with permeability across Caco-2
monolayers can provide a good prediction of bioavailability for
oral formulations. In similar fashion, simulated lung fluids may
also be a tool to assess orally inhaled formulations. Many versions
of this have been assessed with similar pH and osmolality but
different amounts of lipid protein and surfactant have been used
and to date a standard has not been fully agreed. The dose level
can also impact the selection of the dissolution model as
mimicking relative distribution and drug loading at an
absorption site can highly influence observed dissolution rates.
The local saturation achieved around dissolving particles, which
is related to the density of deposition, may cause interference
between dissolving individual particles. This would be different to
the dissolution from a single agglomerate of drug, but the dose
would look same. As such, structure of the deposited particle is
also a key factor. This is complicated by the different absorption
rates in different areas of the lung and the fact that, as particles
can be removed by mucociliary clearance, there is a temporal
aspect to studies that needs to be understood. As such, similar to
oral absorption the speed of dissolution can highly influence
availability for poorly water-soluble drugs.
In closing his presentation, the message was reiterated that the
formulation scientist plays a crucial role in determining success of
early development programs for both new chemical entities and
generic medicines. Work that has been ongoing to produce a
better understanding of the biological and physiochemical
processes behind inhaled delivery implies that in the future
drug candidates for pulmonary delivery should be more
scientifically understood and less of a “black box” approach.
Simulation and In Silico Environment in
Phase I Trials: Dr. Marco Siccardi,
University of Liverpool, United Kingdom
Dr. Siccardi discussed how advances in mechanistic and
computational pharmacokinetic modeling have provided
valuable tools that can be used to rationalize and facilitate the
process of drug development.
Computational pharmacokinetic modeling techniques are
frequently used to provide insights into drug disposition and
to aid in selecting optimal drug candidates for development,
predict human dosing from preclinical pharmacokinetic and
pharmacodynamic data and simulate clinical scenarios to
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optimize patient management. The presentation was opened with
reminding the audience that drugs have traditionally been
evaluated for their safety and efficacy using randomized
control trials. One limitation with this approach is in
establishing how such drugs are likely to act in the real-life,
clinical setting. The complex nature of human diseases,
significant variations between individuals and the variability in
the disposition challenges our ability to predict how new agents
might affect patients. The solution has been to establish a
molecular profile for a drug based on the available laboratory
and clinical information.
Through the use of simulation and in silico clinical trials, we
have introduced the possibility of bridging the gap between the
limited information available in the preclinical setting and a
broader understanding of a molecule’s performance in early
phase clinical development. A specific benefit of in silico
strategies is their ability to generate large amounts of data
from the information provided to; data which can then be
used to understand underpinning mechanisms, simulate
relevant scenarios, and select suitable candidates.
Insight acquired from these processes can accelerate the
development of novel therapies and advanced new materials.
The synthesis of data introduces an additional aspect of research
that has the potential to streamline the drug development and
regulatory process as well as reduce the burden of preclinical
testing while also introducing an opportunity to optimize clinical
trial designs. Dr. Siccardi proceeded to illustrate the potential of
simulation with past examples where modeling was employed to
i) identify patient characteristics and ADME processes
influencing the efficacy and toxicity of therapy; ii) optimize
dosing strategy; iii) streamline the drug development and
regulatory process and; iv) develop novel formulations.
In HIV therapy, patient characteristics and their
pharmacokinetics to markedly impact on the efficacy and
toxicity of medicines. Although a plethora of anti-HIV
medications have been proposed over the past 2 decades, the
challenge has been identifying the optimal candidates on which to
best focus resources. Traditional comparison of clinical
performance takes time and can put the lives of test subjects
at risk. Computational pharmacokinetic modeling can use actual
data in the laboratory to characterize each of the different
mechanisms that influence drug disposition. Quantitative
structure activity relationship (QSAR) relates to the
mathematical relationship between biological activity of a
molecular system and its physiochemical and geometric
properties that dictate characteristics such as: blood plasma
ratio, fraction unbound, plasma stability, hepatic clearance,
and renal clearance. Rational evaluation of QSAR models can
be used to identify the most promising anti HIV drug candidates.
The integration of potency data from large datasets predicts
theoretical pharmacokinetics and validates preliminary
simulations of theoretical dosing strategies. Furthermore, data
harmonization in a computational environment means these
models can be used to identify key variables and generate
molecular predictions for candidate optimization.
Patient adherence to specified dosing regimens can be a major
reason for treatment failure in that they can easily end up with
suboptimal therapy. Often, the reason for non-adherence is
associated with a dislike for a drugs route of administration
for example, many patients find injections unpleasant. The use
of Long Acting Extended Release Antiretroviral Resource
Program (LEAP) studies were discussed and the use of
implanted devices which release anti-retroviral drug over time
negating the need for regular injections. He spoke about how the
introduction of micro-needle array patches, solid-coated, non-
biodegradable materials that penetrate the visible epidermis
providing access to the dermis, provide a patient friendly, low
cost and minimally invasive and pain-free route of drug delivery.
As such, they have the potential to improve patient adherence.
Drug release from nano-particulate formulation can act as the
rate limiting step impacting on local and systemic delivery.
Modeling has been able to provide insight into the
performance of existing twice monthly injections versus
monthly intradermal patch applications.
Despite the different experimental methods available for
characterizing drug-drug interactions, predicting how the
various different biological systems responsible for disposition
can challenge dose optimization in certain population groups. For
example, dose optimization is a particular issue in neonates since
their immature ontogeny and ongoing system development can
complicate scaling of doses. The use of physiologically based
pharmacokinetic modeling was described as a method to predict
drug-drug interaction through estimating enzyme modulation.
This approach can be used to minimize the potential for
interaction and the risk of adverse events and facilitating dose
optimization.
In his final example of modeling, the concept of using patient
ADME characteristics to estimate potential efficacy and toxicity
of drugs. The variety of shapes and sizes of the human body
brings challenges when determining drug disposition. For
example, functions such as cytochrome enzyme expression,
organ blood flows and volume and gastrointestinal physiology
vary in neonates, overweight patients and the elderly. Equally,
drug dispositionmay be affected by comorbidities such as renal or
hepatic impairment. Our understanding of how the catalytic
activity of key enzymes markedly change in the first years of
life, such as the different expression of CYP3A4 and CYP3A7 at
5–7 days old and 3+ months, can help us predict the
pharmacokinetics profile of certain drugs. Modeling with
PBPK has been used to optimize dolutegravir in neonates
(Bunglawala et al., 2019). This particular patient group
represent a vulnerable population where the combination of
a rapidly developing physiology and immature ontogeny can
complicate dose scaling. And yet, clinical trials in neonate are
difficult to rationalize in terms of risk as it can be challenging to
determine the optimal dose to test. In this case, in silico
predictions informed dosing selection, removing the need
for ultra-safe subtherapeutic starting doses, accelerating
registration.
The presentation was concluded with stressing the importance
of artificial intelligence in acquiring a deeper understanding of
pharmacokinetics and optimizing existing therapies. Machine
learning is a method of data analysis that automates model
building. As a specific branch of artificial intelligence, it
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assumes that “systems” can learn from the data they are provided
with, identify underlying patterns and (eventually) make
objective conclusions with minimal human intervention.
Artificial intelligence can facilitate the prediction of the
magnitude in drug-drug interactions, help design novel
formulations and establish efficacious dosing in niche
populations. Thus, the identification of dose adjustments can
help with upcoming rational designs of future studies,
revolutionizing the drug development process.
Data Driven Transformation in Drug
Development: Dr. Satnam Surae,
Aigenpulse Platform
Dr. Satnam Surae opened his presentation by describing how
evolving technological landscapes are stimulating the prevalence
of data science literacy in early phase drug development and how
data-driven companies employing integrated and advanced
analytics are out performing their competitors outside the
pharmaceutical industry. Everyone is aware of the
productivity challenges faced by the industry; that spending
on research and development is increasing while the return in
terms of the number of regulatory approvals of new
therapeutic agents has been disappointing. To gain a
competitive edge it will be necessary for pharmaceutical
companies to embrace the innovations around data science
and apply this new-found understanding to drive drug
discovery, empowering research, and development and thus
ensuring a sustainable future.
Over the last 4 decades there has been substantial growth in
the amounts of large and small data accumulated in early phase
drug development although there have been many challenges in
the accessibility and quality of this data. For example, a broad
variety of experimental outputs are generated when
constructing the preclinical packaging and yet the result is
often poor quality, incomplete data. The data accumulated
are often recorded in proprietary formats and protected by
security and data permissions and yet these data could provide
value beyond registration packages. A shifting landscape in
machine, active and cloud-learning data streams as yet limits
the transferability of this research data restricting how it may be
interrogated.
Web-lab scientists are advised to becomemore technologically
aware and make better decisions based on data-driven ideas. Data
bridges and open data standards are being promoted in the
research and development environment to better organize
research data making it easier to share and exploit. But
initiatives are required to better promote research computing
and support the rapid deployment of scalable tools, e.g.,
containerization and cloud deployment. Dr. Surae predicted
that code versioning, testing and output validation as well as
agile methodologies will become prominent in the industry and
encourage better practice.
Bioinformatics and computational biology are required to
bridge the gap between wet lab, data science, software
engineering, and information technology. Instead of needing
to ask permission and manual handling and data movement,
computational biologists and bioinformaticians should be able to
push and pull data between systems. It can be predicted that
companies and/or scientists that fail to adopt advanced data
technologies will be superseded and outcompeted by those
who do. To resolve this, it was proposed that the industry
adopt a philosophy that encapsulate six key components:
measuring, understanding and learning; the set of experiments
identified; data generated; data ingested and processed; analysis of
the data context; the training and testing of the models and new
updated insights. He predicted that this would assist in the
understanding of experiments and their success criteria; draw
attention to metadata quality; understand objectives and flexible
analytical pipelines; apply the best active and machine learning
methods to scientifically challenge and interpret output to drive
the delivery of new scientific insights.
Specialist expertise in data manipulation has traditional only
been available in academic institutions and finance houses are
now not only emerging through a new generation of start-up
companies providing services to the pharmaceutical industry but
also through huge data-driven organizations like Google, Apple,
and Amazon, who are beginning to show an interest in the
healthcare sector. It was noted that those companies that can
harness such knowledge are poised to make significant break-
throughs, not only in terms of pipelines and processes, but also in
the way that the pharma businesses will control, shape, and steer
data through their entire organization.
Classic drug discovery pipelines of the future were suggested to
become more agile if data driven, active and machine learning
applications were implemented from the outset and maintained
through to the final stages of the development process. He
described how data can be used to predict efficacy, toxicology,
and manufacturing issues in the transition from lead
identification to candidate optimization stage and eventually
through to target validation. He predicted that this would have
a ripple effect on the other transition stages where integrated data
could predict potential biomarkers, disease progression, and
treatment response. Effectively, data can be enriched by
breaking down silos within and between the teams and by
differentiating “positive” and “negative” data using labels.
Introducing appropriate anonymization allows in-house safety
databases on subjects exposed to candidate molecules to be
enriched from external resources, e.g., genomics England.
Metadata could be used to standardize vocabularies and units
across clinical data sets which would aid with code versioning,
testing and validation processes to bridge communicators.
The Aigenpulse platform was introduced as one such solution
to organizing scientific data efficiently; where deployment of their
experimental suite is expected to promote re-usability, increase
efficiency, and drive data quality.
The presentation was concluded with the concept that only by
becoming part of the data revolution will life science
organizations be able to remain dynamic, innovative, and
relevant. In the coming decade, winners in the race for total
digital transformation will be those that adapt agile and integrated
approaches to data management and manipulation.
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CONCLUSION
The 2019 AHPPI meeting focused on a selection of the changes
in early phase drug development that have occurred in the last
4 decades, current innovations in pharmaceutical medicine and
the future challenges facing the pharmaceutical industry. A
wide range of exciting topics were presented and discussed
including advances in and the future of biologics and how the
industry and regulatory agencies are adapting to novel trial
designs. The event included a lively discussion over the future
of placebo subjects in Phase I trials and the keynote address on
addressing the issue of delivering successful change. Further
developments that were discussed included the
biopharmaceutical impact of the delivery of molecular drugs
via non-oral routes of administration as well as the simulation
and in silico environment in Phase I trials and data driven
transformation in drug development. In closing the meeting,
the AHPPI Chairman, Dr. Tim Hardman, summarized how the
topics discussed demonstrated how the pharmaceutical
industry is quickly changing and the pharmaceutical
industry in the next 10 years will likely be very different.
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